![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novartis and Incyte Plan Second Phase 3 Trial of Jakafi for COVID-19
Novartis and Incyte Plan Second Phase 3 Trial of Jakafi for COVID-19
![Jakafi logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/_Jakafi-logo.gif?t=1588802838&width=430)
Incyte and Novartis are planning a second phase 3 clinical trial in the U.S. of their JAK inhibitor Jakafi (ruxolitinib) as a COVID-19 treatment.
The trial will evaluate the drug’s safety and efficacy along with the standard of care, compared to standard-of-care therapy alone in COVID-19 patients on mechanical ventilation and who have acute respiratory distress syndrome.
The companies launched a phase 3 trial of Jakafi last month to treat cytokine storm – an immune response in which the body attacks its own cells – in COVID-19 patients.
Upcoming Events
-
21Oct